Vyvanse, also known as lisdexamfetamine, received its initial U.S. Food and Drug Administration (FDA) approval on February 23, 2007, for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 12 [1].
When did Vyvanse get approved for adults?
An expanded indication for Vyvanse in adults with ADHD was approved by the FDA on April 17, 2008 [1].
What is the active ingredient in Vyvanse?
The active ingredient in Vyvanse is lisdexamfetamine dimesylate [1]. It is a prodrug of dextroamphetamine, meaning it is converted to its active form in the body [2].
How does Vyvanse work for ADHD?
Vyvanse is a central nervous system (CNS) stimulant. It is thought to work by increasing the levels of certain neurotransmitters, such as dopamine and norepinephrine, in the brain. These neurotransmitters play a role in regulating attention, impulsivity, and hyperactivity [2].
When does Vyvanse patent expire?
The primary U.S. compound patent for Vyvanse (lisdexamfetamine dimesylate) is expected to expire in 2023 [3]. However, multiple patents related to its formulation, method of use, and manufacturing processes may extend market exclusivity beyond this date [3]. Information on specific patent expiration dates can be found on DrugPatentWatch.com [3].
What are the potential side effects of Vyvanse?
Common side effects of Vyvanse include decreased appetite, dry mouth, insomnia, weight loss, and anxiety [1]. Less common but serious side effects can include cardiovascular problems, psychiatric issues, and potential for abuse or dependence [1].
Are there alternatives to Vyvanse for ADHD treatment?
Yes, several alternative medications are available for ADHD treatment. These include other stimulant medications like methylphenidate (e.g., Ritalin, Concerta) and other amphetamine-based stimulants. Non-stimulant options are also available, such as atomoxetine (Strattera) and certain antidepressants like bupropion (Wellbutrin) [4].
What is the difference between Vyvanse and Adderall?
Both Vyvanse and Adderall are stimulant medications used to treat ADHD, but they contain different active ingredients. Adderall is a combination of amphetamine and dextroamphetamine salts, while Vyvanse contains lisdexamfetamine dimesylate, which is converted to dextroamphetamine in the body [5]. Their formulations and durations of action can also differ [5].
Can generics of Vyvanse be made before patent expiry?
The ability to market generic versions of Vyvanse before the expiration of all relevant patents depends on the patent landscape and any legal challenges. If patents are successfully challenged or expire, generic manufacturers may be able to enter the market [3].
What clinical data supports Vyvanse's effectiveness?
Clinical trials demonstrated Vyvanse's efficacy in reducing ADHD symptoms in children, adolescents, and adults. Studies measured improvements in attention, impulse control, and hyperactivity compared to placebo [1].
Who manufactures Vyvanse?
Vyvanse is manufactured by Takeda Pharmaceutical Company [1].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021878s006,021879s005lbl.pdf
[2] https://www.vyvanse.com/how-vyvanse-works
[3] https://www.drugpatentwatch.com/p/vyvanse
[4] https://www.additudemag.com/medication-for-adhd-stimulants-non-stimulants/
[5] https://www.webmd.com/add-adhd/adderall-vs-vyvanse